Two-tiered biological containment strategy for Lactococcus lactis-based vaccine or immunotherapy vectors

References

• Bahey-El-Din M, Casey PG, Griffin BT, Gahan CGM. Lactococcus lactis-expressing listeriolysin O (LLO) provides protection and specific CD8(+) T cells against Listeria monocytogenes in the murine infection model. Vaccine 2008; 26:5304 - 14; http://dx.doi.org/10.1016/j.vaccine.2008.07.047; PMID: 18691625
   PubMed Web of Science ®Google Scholar
• Bahey-El-Din M, Casey PG, Griffin BT, Gahan CG. Efficacy of a Lactococcus lactis ΔpyrG vaccine delivery platform expressing chromosomally integrated hly from Listeria monocytogenes.. Bioeng Bugs 2010; 1:66 - 74; http://dx.doi.org/10.4161/bbug.1.1.10284; PMID: 21327128
   PubMedGoogle Scholar
• Bahey-El-Din M, Casey PG, Griffin BT, Gahan CGM. Expression of two Listeria monocytogenes antigens (P60 and LLO) in Lactococcus lactis and examination for use as live vaccine vectors. J Med Microbiol 2010; 59:904 - 12; http://dx.doi.org/10.1099/jmm.0.018770-0; PMID: 20488938
   PubMed Web of Science ®Google Scholar
• Bahey-El-Din M, Gahan CGM. Lactococcus lactis-based vaccines: current status and future perspectives. Hum Vaccin 2011; 7:106 - 9; http://dx.doi.org/10.4161/hv.7.1.13631; PMID: 21263226
   PubMed Web of Science ®Google Scholar
• Bahey-El-Din M. Lactococcus lactis-based vaccines from laboratory bench to human use: an overview. Vaccine 2012; 30:685 - 90; http://dx.doi.org/10.1016/j.vaccine.2011.11.098; PMID: 22154771
   PubMed Web of Science ®Google Scholar
• Caluwaerts S, Vandenbroucke K, Steidler L, Neirynck S, Vanhoenacker P, Corveleyn S, Watkins B, Sonis S, Coulie B, Rottiers P. AG013, a mouth rinse formulation of Lactococcus lactis secreting human Trefoil Factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis. Oral Oncol 2010; 46:564 - 70; http://dx.doi.org/10.1016/j.oraloncology.2010.04.008; PMID: 20542722
   PubMed Web of Science ®Google Scholar
• Wells JM, Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol 2008; 6:349 - 62; http://dx.doi.org/10.1038/nrmicro1840; PMID: 18345021
   PubMed Web of Science ®Google Scholar
• Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B, Cox E, Remon JP, Remaut E. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol 2003; 21:785 - 9; http://dx.doi.org/10.1038/nbt840; PMID: 12808464
   PubMed Web of Science ®Google Scholar
• Steidler L, Rottiers P. Therapeutic drug delivery by genetically modified Lactococcus lactis.. Ann N Y Acad Sci 2006; 1072:176 - 86; http://dx.doi.org/10.1196/annals.1326.031; PMID: 17057198
   PubMed Web of Science ®Google Scholar
• Vandenbroucke K, Hans W, Van Huysse J, Neirynck S, Demetter P, Remaut E, Rottiers P, Steidler L. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology 2004; 127:502 - 13; http://dx.doi.org/10.1053/j.gastro.2004.05.020; PMID: 15300583
   PubMed Web of Science ®Google Scholar
• Wang Z, Gao J, Yu Q, Yang Q. Oral immunization with recombinant Lactococcus lactis expressing the hemagglutinin of the avian influenza virus induces mucosal and systemic immune responses. Future Microbiol 2012; 7:1003 - 10; http://dx.doi.org/10.2217/fmb.12.69; PMID: 22913358
   PubMed Web of Science ®Google Scholar
• Wells J. Mucosal vaccination and therapy with genetically modified lactic acid bacteria. Annu Rev Food Sci Technol 2011; 2:423 - 45; http://dx.doi.org/10.1146/annurev-food-022510-133640; PMID: 22129390
   PubMed Web of Science ®Google Scholar
• Bolhassani A, Zahedifard F. Therapeutic live vaccines as a potential anticancer strategy. Int J Cancer 2012; 131:1733 - 43; http://dx.doi.org/10.1002/ijc.27640; PMID: 22610886
   PubMed Web of Science ®Google Scholar
• Ribelles P, Benbouziane B, Langella P, Suárez JE, Bermúdez-Humarán LG. Protection against human papillomavirus type 16-induced tumors in mice using non-genetically modified lactic acid bacteria displaying E7 antigen at its surface. Appl Microbiol Biotechnol 2013; 97:1231 - 9; http://dx.doi.org/10.1007/s00253-012-4575-1; PMID: 23212671
   PubMed Web of Science ®Google Scholar
• Takiishi T, Korf H, Van Belle TL, Robert S, Grieco FA, Caluwaerts S, Galleri L, Spagnuolo I, Steidler L, Van Huynegem K, et al. Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J Clin Invest 2012; 122:1717 - 25; http://dx.doi.org/10.1172/JCI60530; PMID: 22484814
   PubMed Web of Science ®Google Scholar
• EU Council Directive 2009/41/EC on the contained use of genetically modified micro-organisms [Internet]. Official Journal L 125, 21/05/2009 P. 0075 - 0097; Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:125:0075:01:EN:HTML - Last accessed May, 21st 2012.
   Google Scholar
• Lee P. Biocontainment strategies for live lactic acid bacteria vaccine vectors. Bioeng Bugs 2010; 1:75 - 7; http://dx.doi.org/10.4161/bbug.1.1.10594; PMID: 21327129
   PubMedGoogle Scholar
• Ahmad SI, Kirk SH, Eisenstark A. Thymine metabolism and thymineless death in prokaryotes and eukaryotes. Annu Rev Microbiol 1998; 52:591 - 625; http://dx.doi.org/10.1146/annurev.micro.52.1.591; PMID: 9891809
   PubMed Web of Science ®Google Scholar
• Leenhouts K, Buist G, Bolhuis A, ten Berge A, Kiel J, Mierau I, Dabrowska M, Venema G, Kok J. A general system for generating unlabelled gene replacements in bacterial chromosomes. Mol Gen Genet 1996; 253:217 - 24; http://dx.doi.org/10.1007/s004380050315; PMID: 9003306
   PubMedGoogle Scholar
• Maguin E, Duwat P, Hege T, Ehrlich D, Gruss A. New thermosensitive plasmid for gram-positive bacteria. J Bacteriol 1992; 174:5633 - 8; PMID: 1324906
   PubMed Web of Science ®Google Scholar
• Law J, Buist G, Haandrikman A, Kok J, Venema G, Leenhouts K. A system to generate chromosomal mutations in Lactococcus lactis which allows fast analysis of targeted genes. J Bacteriol 1995; 177:7011 - 8; PMID: 8522504
   PubMed Web of Science ®Google Scholar
• Dower WJ, Miller JF, Ragsdale CW. High efficiency transformation of E. coli by high voltage electroporation. Nucleic Acids Res 1988; 16:6127 - 45; http://dx.doi.org/10.1093/nar/16.13.6127; PMID: 3041370
   PubMed Web of Science ®Google Scholar
• Geertsma ER, Poolman B. High-throughput cloning and expression in Lactococcus lactis. Protocol Exchange [Internet] 2007; Available from: http://www.nature.com/protocolexchange/protocols/287
   Google Scholar
• Gerber SD, Solioz M. Efficient transformation of Lactococcus lactis IL1403 and generation of knock-out mutants by homologous recombination. J Basic Microbiol 2007; 47:281 - 6; http://dx.doi.org/10.1002/jobm.200610297; PMID: 17518422
   PubMed Web of Science ®Google Scholar
• Jensen PR, Hammer K. Minimal Requirements for Exponential Growth of Lactococcus lactis.. Appl Environ Microbiol 1993; 59:4363 - 6; PMID: 16349136
   PubMed Web of Science ®Google Scholar